New Zealand markets closed

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.1650-0.0098 (-5.61%)
At close: 04:00PM EDT
0.1700 +0.00 (+3.03%)
After hours: 07:55PM EDT

Corbus Pharmaceuticals Holdings, Inc.

500 River Ridge Drive
Norwood, MA 02062
United States
617 963 0100
https://www.corbuspharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees41

Key executives

NameTitlePayExercisedYear born
Dr. Yuval Cohen Ph.D.CEO & Director846.92kN/A1975
Mr. Sean F. Moran CPA, M.B.A., CPA, MBAChief Financial Officer542kN/A1958
Mr. Craig Stuart Millian M.B.A.Chief Operating Officer542kN/A1969
Dr. Rachael Brake Ph.D.Chief Scientific OfficerN/AN/A1972
Ted JenkinsSr. Director of Investor Relations & Corp. CommunicationsN/AN/AN/A
Ms. Lindsey SmithHead of Corp. Communications & Patient AdvocacyN/AN/AN/A
Ms. Christina BertschHead of HRN/AN/AN/A
Scott ConstantineSr. Director & Head of Clinical OperationsN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Corporate governance

Corbus Pharmaceuticals Holdings, Inc.’s ISS governance QualityScore as of 1 October 2022 is 7. The pillar scores are Audit: 9; Board: 6; Shareholder rights: 4; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.